Medical DirectorRush Hemophilia and Thrombophilia Center, Rush University Medical Center, Chicago, IL, USAChicago, Illinois, United States
PB0233 - Assessing factor consumption and bleeding outcomes of prophylaxis with three commonly prescribed factor IX products for hemophilia B: a retrospective medical chart analysis in the United States
Sunday, June 23, 202413:45 – 14:45 ICT
OC 50.2 - Long-term outcomes with efanesoctocog alfa prophylaxis for previously treated children with severe hemophilia A, an interim analysis of the phase 3 XTEND-ed study
Tuesday, June 25, 202409:45 – 10:00 ICT
